Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-08-29
2006-08-29
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S232100, C424S093200, C424S093600, C435S235100, C435S236000, C435S320100
Reexamination Certificate
active
07097842
ABSTRACT:
The invention concerns the use of a virus for the preparation of a medicament for the vaccination, treatment, or protection, of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group as the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumor antigens, wherein the tumor antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to (i) increase the level of factors which activate dendritic cells or their precursor cells, (ii) and/or to increase the number of dendritic cells or their precursor cells, (iii) and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.
REFERENCES:
patent: 3914408 (1975-10-01), Mebus
patent: 4191745 (1980-03-01), Mayr et al.
patent: 5338683 (1994-08-01), Paoletti et al.
patent: 5770212 (1998-06-01), Falkner et al.
patent: 5843456 (1998-12-01), Paoletti et al.
patent: 6204250 (2001-03-01), Bot et al.
patent: 6605465 (2003-08-01), Paoletti
patent: 6685950 (2004-02-01), Weber et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6805870 (2004-10-01), Mayr et al.
patent: 90/12882 (1990-11-01), None
patent: 95/22978 (1995-08-01), None
patent: WO 95/22978 (1995-08-01), None
patent: WO 97/31119 (1997-08-01), None
patent: 98/17283 (1998-04-01), None
patent: 01/68820 (2001-09-01), None
patent: WO 01/68820 (2001-09-01), None
patent: 02/42480 (2002-05-01), None
patent: WO 02/42480 (2002-05-01), None
Watts et al (Nature Medicine 5:427-430, 1999).
Siegrist (Vaccine 19 :3331-3346, 2001).
Siegrist et al (Vaccine 16: 1473-1478, 1998).
Suarez et al (Obstetrics & Gynecology 100:87-93, Jul. 2002).
Zhu et al (Virology 276:202-213, 2000).
Roberts (Drug Discovery Today 7:936-937, 2002).
Monteil et al (Journal of General Virology 78:3303-3310, 1997).
Siegrist (Vaccine 19:3331-3346, 2001; International Reviews of Immunology 19:195-219, 2000.
Yong-de-Zhu, et al.; Virology 276, 202-213 (2000); Evaluation of Recombinant Vaccinia Virus—Measles Vaccines in Infant Rhesus Macaques with Preexisting Measles Antibody.
Jiri Kovarik, et al.; Virology 285, 12-20 (2001); Induction of Adult-like Antibody, Th1, and CTL Responses to Measles Hemagglutinin by Early Life Murine Immunization with An Attenuated Vaccinia-Derived NYVAC(K1L) Viral Vector.
Gilles Dadaglio, et al.; The Journal of Immunology 168, 2219-2224 (2002); Efficient In Vivo Priming of Specific Cytotoxic T Cell Responses by Neonatal Dendritic Cells.
John Paul Ridge, et al.; Science 271, 1723-1726 (Mar. 22, 1996); Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells.
B. Vilsmeier, Paraimmunity inducing effects of vaccinia strain MVA. (1999) Berl. Münch. Tierärztl. Wschr. 112:329-333.
A. Mayr, Paraspezifische Vaccinen aus Pockenviren (Paramunitätsinducer): eine neue Art von Impfstoff (1999) Ärztezeitschrift für Naturheilverfahren 40, 8 pp. 550-557.
M. Franchini, et al., Protective T-Cell-Based Imminity Induced in Neonatal Mice by a Single Replicative Cycle of Herpes Simplex Virus. (2001) Journal of Virology 75:83-89.
K. Stittelaar, et al. Protective Immunity in Macaques Vaccinated with a Modified Vaccinia Virus Ankara-Based Measles Virus Vaccine in the Presence of Passively Acquired Antibodies. (2000) Journal of Virology 74:4236-4243.
A. Mayr Zbl. Vet. Med. B, TC marker of the attenuated vaccinia vaccide strain “MVA” in human cell cultures and protective immunization against orthopox diseases in animals. (1976) 23:417-430.
A. Bot, et al. Induction of immunological memory in baboons primed with DNA vaccine as neonates. (2001) Vaccine 19:1960-70 (Abstract only).
C. McLean, et al. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. (1996) Vaccine 14:987-92, (Abstract only).
M. Monteil,et al. Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth. (1997) Journal of General Virology 78:3303-10.
C. Siegrist Vacciniation in the neonatal period and early infancy. (2000) Int. Rev Immunol. 19:195-219, (Abstract only).
I. Belyakov, et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses, (2003) Proc. Natl. Acad. Sci. USA 100:9458-63.
Centers for Disease Control and Prevention (CDC) “Smallpox Fact Sheet” (2003).
B. Vilsmeier, Berl. Munch. Tierarztl. Wochenschrift 112, 329-333 (1999).
MVA-BN: A safe and efficacious smallpox vaccine option. Advances in Life Science Feb. 2, 2002, http://www.advancesinlifescience.com/management—2.htm.
Roduit, et al. Immunogenicity and Protective Efficacy of Neonatal Vaccination againstBordetella pertussisin a Munine Model: Evidence for Early Control of Pertussis. Infection and Immunity, Jul. 2002, p. 3521-3528.
Engerix®-B Leaflet of May 9, 2005, GlaxoSmithKline Biologicals SA.
Moss, B. (1996) Geneically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
Stittelaar, et al. (2000) Protective Immunity in Macaques Vaccinated with a Modified Vaccinia Virus Andara-Based Measles Virus Vaccine in the Presence of Passively Acquired Antibodies. Journal of Virology 74:4236-4243.
International Preliminary Examination Report, dated Jan. 11, 2006, four (4) pages.
Tartaglia, et al. “NYVAC: a highly attenuated stratin of vaccinia virus” Virology 1992, vol. 188, pp. 217-232.
Kovarik, et al. “Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC (K1L) viral vector” Virology Jun. 20, 2001, vol. 285, pp. 12-20.
Kazanji, et al. “Immunogenicity and protective efficacy of recombinant human T-cell leukaemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus)” Journal of Virology, Jul. 2001, vol. 75(13), pp. 5939-5948.
Chaplin Paul
Suter Mark
Vollstedt Sabine
Bavarian Nordic A/S
Hueschen and Sage
Mosher Mary E.
LandOfFree
Modified vaccinia virus ankara for the vaccination of neonates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vaccinia virus ankara for the vaccination of neonates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vaccinia virus ankara for the vaccination of neonates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714675